Xuefei Liu

Xuefei Liu

Auto-generated profile, based on publicly available information

Xuefei Liu

Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
ZCZhihang Chen
Zhihang Chen
ZLZiwei Luo
Ziwei Luo
DZDi Zhang
Di Zhang
HLHuiqin Li
Huiqin Li
XLXuefei Liu
Xuefei Liu
ZZZhixiang Zuo
Zhixiang Zuo
Immunotherapy is a promising cancer treatment method; however, only a few patients benefit from it. The development of new immunotherapy strategies and effective biomarkers of response and resistance is urgently needed. Recently, high-throughput bulk and single-cell gene expression profiling technologies have generated valuable resources. However, these resources are not well organized and systematic analysis is difficult. Here, we present TIGER, a tumor immunotherapy gene expression resource, which contains bulk transcriptome data of 1508 tumor samples with clinical immunotherapy outcomes and 11,057 tumor/normal samples without clinical immunotherapy outcomes, as well as single-cell transcriptome data of 2,116,945 immune cells from 655 samples. TIGER provides many useful modules for analyzing collected and user-provided data. Using the resource in TIGER, we identified a tumor-enriched subset of CD4+ T cells. Patients with melanoma with a higher signature score of this subset have a significantly better response and survival under immunotherapy. We believe that TIGER will be helpful in understanding anti-tumor immunity mechanisms and discovering effective biomarkers. TIGER is freely accessible at http://tiger.canceromics.org/.

4 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMei Lin
Mei Lin
XZXiao-Long Zhang
Xiao-Long Zhang
RYRui You
Rui You
YLYou-Ping Liu
You-Ping Liu
HCHongmin Cai
Hongmin Cai
MCMing-Yuan Chen
Ming-Yuan Chen
It is critical to understand factors associated with nasopharyngeal carcinoma (NPC) metastasis. To track the evolutionary route of metastasis, here we perform an integrative genomic analysis of 163 matched blood and primary, regional lymph node metastasis and distant metastasis tumour samples, combined with single-cell RNA-seq on 11 samples from two patients. The mutation burden, gene mutation frequency, mutation signature, and copy number frequency are similar between metastatic tumours and primary and regional lymph node tumours. There are two distinct evolutionary routes of metastasis, including metastases evolved from regional lymph nodes (lymphatic route, 61.5%, 8/13) and from primary tumours (hematogenous route, 38.5%, 5/13). The hematogenous route is characterised by higher IFN-γ response gene expression and a higher fraction of exhausted CD8+ T cells. Based on a radiomics model, we find that the hematogenous group has significantly better progression-free survival and PD-1 immunotherapy response, while the lymphatic group has a better response to locoregional radiotherapy.

11 January 2022 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
XPXu-Ying Pei
Xu-Ying Pei
XLXue-Fei Liu
Xue-Fei Liu
XZXiangyu Zhao
Xiangyu Zhao
MLMeng Lv
Meng Lv
XMXiao-Dong Mo
Xiao-Dong Mo
Xiaojun HuangXiaojun Huang
Xiaojun Huang
Adoptive transfer of cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CMV-CTLs) from original transplant donors or third-party donors was effective for the treatment of CMV infection after allogenic stem cell transplantation (allo-SCT), but the antiviral activity of CMV-CTL types has not been compared. To determine whether third-party CMV-CTLs provide comparable long-term antiviral efficacy to transplant donor CMV-CTLs, we first compared the antiviral abilities of transplant donors and third-party CMV-CTLs for treatment of CMV infection in two mouse models, compared the in vivo recovery of CMV-specific immunity, and analyzed the underlying mechanisms driving sustained antiviral immunity. The results showed that both donor and third-party CMV-CTLs effectively combated systemic CMV infection by reducing CMV pathology and tumor burden 28 days postinfusion. The in vivo recovery of CMV-specific immunity after CMV-CTL infusion was comparable in both groups. A detailed analysis of the source of recovered CMV-CTLs showed the proliferation and expansion of graft-derived endogenous CMV-CTLs in both groups. Our clinical study, which enrolled 31 patients who received third-party CMV-CTLs and 62 matched pairs of individuals who received transplant donor CMV-CTLs for refractory CMV infection, further showed that adoptive therapy with donor or third-party CMV-CTLs had comparable clinical responses without significant therapy-related toxicity. We observed strong expansion of CD8+ tetramer+ T cells and proliferation of recipient endogenous CMV-CTLs after CMV-CTL infusion, which were associated with a reduced or cleared viral load. Our data confirmed that adoptive therapy with third-party or transplant donor CMV-CTLs triggered comparable antiviral responses to CMV infection that might be mediated by restoration of endogenous CMV-specific immunity.

14 April 2022 in Genes
Verified
Journal Article
Open access
PDF file
LDLianhui Duan
Lianhui Duan
XLXuefei Liu
Xuefei Liu
ZLZiwei Luo
Ziwei Luo
CZChen Zhang
Chen Zhang
CWChun Wu
Chun Wu
TSTian Shao
Tian Shao
Background: GNG4, a member of the G-protein γ family, is a marker of poor overall survival (OS) rates in some malignancies. However, the potential role of GNG4 in bladder cancer (BLCA) is unknown. It is also unclear whether GNG4 may be utilized as a marker to guide chemotherapy or immunotherapy. Methods: Single-cell RNA sequencing data were used to explore the expression of GNG4 in tumor microenvironment of BLCA. Bulk RNA sequencing data from TCGA were used to evaluate the relationship between GNG4 expression and biological features, such as immune cell infiltrations and gene mutations. The associations between GNG4 expression and survival in BLCA patients under or not under immunotherapy were evaluated using seven BLCA cohorts. Results: GNG4 was specifically expressed in exhausted CD4+ T cells. And the high expression of the GNG4 was associated with high level of immune cell infiltration. The high-GNG4-expression group displayed a better response to immunotherapy, whereas patients in the low-GNG4-expression group often benefited from chemotherapy. Moreover, the high-GNG4 group was more similar to the basal group, whereas the low-GNG4 group was similar to the luminal group. Conclusions: GNG4 may be a potential biomarker for the prediction of the response to therapy in BLCA. Higher GNG4 expression can be used as a predictor of response to immunotherapy, and lower GNG4 expression can be used as a predictor of response to chemotherapy.

4 December 2025 in Cancer Research
Verified
Journal Article
Closed access
YCYixin Cheng
Yixin Cheng
GHGuanyin Huang
Guanyin Huang
XLXuefei Liu
Xuefei Liu
CWChun Wu
Chun Wu
JLJingru Lian
Jingru Lian
XHXIN HONG
XIN HONG
Intratumoral heterogeneity supports cancer progression and metastasis while limiting therapeutic efficacy. Comprehensive biological characterization of heterogeneous subclones in breast cancer may hold promise in battling against this deadly disease. Using single-cell transcriptomic analysis and in situ profiling of primary tumors, metastases, and circulating tumor cells from multiple patients with breast cancer, we identified a unique EPCAM+ CD68+ TREM2+ tumor subpopulation, likely resulting from the fusion of tumor cells and lipid-associated macrophages (LAM). The presence of these tumor–LAM fusion cells in the blood or in distinct metastatic sites was significantly correlated with metastatic progression. Stable fusion clonal lines established in vitro exhibited substantially enhanced proliferation, tumor initiation, and metastasis formation in mice. Integrative molecular and functional analyses revealed a critical role for SNX10 in mediating tumor–LAM fusion. Mechanistically, SNX10 physically interacted with the phospholipid scramblase ANO6 and maintained its protein stability by suppressing proteasome-mediated degradation. Furthermore, the transcription factor CBX3 directly targeted SNX10 promoter and modulated its expression. Fusion cells accumulated abundant intracellular lipid droplets and were highly sensitive to simvastatin treatment in vitro and in vivo. Together, this study uncovered that CBX3–SNX10–ANO6 signaling facilitates generation of an aggressive tumor-LAM fusion cell subpopulation that promotes metastasis, revealing an alternative metastatic mechanism and exposing putative therapeutic vulnerabilities. Significance: Single-cell transcriptomic profiling combined with functional and clinical validation identifies fusion of tumor cells and lipid-associated macrophages mediated by the CBX3–SNX10–ANO6 axis as a potentially targetable mechanism driving cancer metastasis.

8 June 2026 in Cancer Discovery
Verified
Journal Article
Closed access
XLXuefei Liu
Xuefei Liu
JTJun Tan
Jun Tan
CWChun Wu
Chun Wu
GHGuanyin Huang
Guanyin Huang
YCYixin Cheng
Yixin Cheng
XHXIN HONG
XIN HONG
Brain metastasis remains a devastating disease with dismal prognosis. How circulating tumor cells (CTC) penetrate the blood–brain barrier (BBB) and reprogram the brain microenvironment remains unclear. Using spatially resolved multi-omics profiling of CTCs and brain metastases, integrated with experimental and clinical analyses, we identified glycoprotein nonmetastatic melanoma protein B (GPNMB) as a CTC-secreted driver of vascular disruption and brain colonization. CBX3 upregulation induced GPNMB expression, which bound endothelial EGFR, triggering CBL-mediated ubiquitination and degradation. Attenuated EGFR signaling suppressed FTO and disrupted endothelial junctions via YTHDF2-dependent TJP1 m6A methylation. Remarkably, GPNMB-induced BBB remodeling promoted immune infiltration via the CXCL12–CXCR4 axis and induced time-course–dependent T-cell exhaustion within the brain microenvironment. Clinically, elevated CBX3+GPNMB+ CTCs and plasma CXCL12 were significantly associated with brain metastasis progression in lung cancer and melanoma. Therapeutically, dual blockade of GPNMB and PD1 enhanced anti–brain metastasis efficacy in mice, unveiling GPNMB as a promising target for precision immunotherapy. Significance: GPNMB is a CTC-secreted driver of BBB disruption and brain colonization via the CBX3-GPNMB–EGFR–FTO–TJP1 axis. GPNMB-induced BBB remodeling promotes CXCL12–CXCR4-mediated immune infiltration and enhances T-cell exhaustion, sensitizing brain metastasis tumors to GPNMB/PD1 dual blockade. CBX3+GPNMB+ CTCs and plasma CXCL12 may serve as noninvasive biomarkers for brain metastasis management.